Target cardiovascular risk rather than cholesterol concentration

BMJ (Online)

Volumn 347, Issue , 2013, Pages 1-2

  Krumholz, Harlan M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; UNITED STATES; BLOOD; CARDIOVASCULAR DISEASES; LIFESTYLE; PRIMARY PREVENTION; PROCEDURES; RISK REDUCTION; METHODOLOGY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK REDUCTION BEHAVIOR;

EID: 84889011531     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f7110     Document Type: Editorial

References (16)

1. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013; published online 7 Nov.
2. Expert Panel. Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148: 36-69.
3. European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-818.
4. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the adult treatment panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012;5: 2-5.
5. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med 2010;152: 69-77.
6. Krumholz HM. Emphasizing the burden of proof: the American College of Cardiology 2008 expert panel comments on the ENHANCE trial. Circ Cardiovasc Qual Outcomes 2010;3: 565-7.
7. Krumholz HM, Hayward RA. Shifting views on lipid lowering therapy. BMJ 2010;341:c3531.
8. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357: 2109-22. (Pubitemid 350146106)
9. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol concentrations receiving intensive statin therapy. N Engl J Med 2011;365: 2255-67.
10. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362: 1563-74.
11. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358: 1431-43. (Pubitemid 351482735)
12. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78.
13. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126: 3097-137.
14. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2013;127: 529-55.
15. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291: 1864-70. (Pubitemid 38509499)
16. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013;382:1680.